CORMEDIX INC CRMD
ASignal's systematic analysis rates CRMD as Neutral.
Reflects the latest available analysis · analyzed Sep 27, 2026
The case on CRMD
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (156.5% YoY)
- High gross and operating margins (90.21% and 42.10%)
- Exceptional return on equity (54.93%)
- Positive free cash flow ($178.14M)
- Net cash position with debt-to-equity of 0.32x
- Oversold RSI at 26.98
- Negative MACD histogram indicating weakening momentum
- Price below 20-day and 50-day moving averages
- High forward P/E (22.43x) relative to PEG ratio (5.61x)
- No Reddit mentions suggesting low retail interest
See the full verdict on CRMD
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CRMD
Most investors never get a second opinion, let alone several. ASignal runs CRMD past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.